Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

2.900 +0.040 (+1.40%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	26,797
Open	2.820
Bid (Size)	2.820 (200)
Ask (Size)	3.100 (900)
Prev. Close	2.860
Today's Range	2.810 - 2.920
52wk Range	2.710 - 48.90
Shares Outstanding	3,192,040
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Performance

YTD	-70.2%	-70.2%
1 Month	-19.2%	-19.2%
3 Month	-38.3%	-38.3%
6 Month	-61.8%	-61.8%
1 Year	-93.8%	-93.8%

More News

Earnings Outlook For Cellectar Biosciences ↗

November 12, 2025

Via Benzinga

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025

November 06, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

A Peek at Cellectar Biosciences's Future Earnings ↗

August 13, 2025

Via Benzinga

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

October 27, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

October 14, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 07, 2025

Via Benzinga

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally ↗

October 07, 2025

Via Stocktwits

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

October 07, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

October 06, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

September 30, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)

September 24, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

September 11, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

September 09, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

September 05, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

September 03, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

August 27, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Cuts Q2 Losses and Expenses ↗

August 14, 2025

Via The Motley Fool

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

August 14, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

August 07, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 30, 2025

Via Benzinga

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

July 02, 2025

From Cellectar Biosciences, Inc.

Via GlobeNewswire

Which stocks are moving on Tuesday? ↗

July 01, 2025

Via Chartmill

Frequently Asked Questions

Is Cellectar Biosciences, Inc. - Common Stock publicly traded?

Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?

Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?

The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market

What is the current price of Cellectar Biosciences, Inc. - Common Stock?

The current price of Cellectar Biosciences, Inc. - Common Stock is 2.900

When was Cellectar Biosciences, Inc. - Common Stock last traded?

The last trade of Cellectar Biosciences, Inc. - Common Stock was at 11/24/25 04:00 PM ET

What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?

The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 9.26M

How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?

Cellectar Biosciences, Inc. - Common Stock has 9M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.